The NFκB pathway was altered in 45% of HMCLs, mostly by inactivating TRAF3 (frame-shift, non-sense mutation, insertion or deletion) or BIRC2/BIRC3 (homozygous deletion) as previously reported in primary myeloma cells [20, 23]. Here, BIRC2 is linked to plasma cell myeloma.